Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MaaT033 in ALS (IASO)
NCT05889572Phase 1Completed
- Sponsor
- MaaT Pharma
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MaaT-033 in amyotrophic lateral sclerosis (ALS), sponsored by MaaT Pharma. Primary endpoint: Incidence of Treatment Emergent Adverse Events (TEAE) grade >3 at Day 84. Started Jun 2023; status: completed.
02
Drugs
MaaT-033
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05889572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05889572.